Abstract: Tumor immune checkpoint inhibitors (ICPis) have been using in patients with malignant tumors more and more widely in recent years. ICPis exhibit good effect on tumors, but also lead to non-specific immune-related adverse events. ICPis-related endocrinopathies include hypophysitis and anterior pituitary dysfunction, thyroid dysfunction, diabetes mellitus, primary adrenal insufficiency, and polyendocrine dysfunction. These diseases are usually not accurately identified and treated in time, sometimes can be life-threatening. This article reviews the research progress in types, incidence, clinical manifestations, prognosis, possible pathogenesis of ICPis-related endocrinopathies and clinical management recommendations, so as to improve the awareness and vigilance of clinicians and patients on the ICPis-related endocrinopathies.